ESMO 2021 | NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the NORSE study, a Phase II trial evaluating erdafitinib, an FGFR inhibitor, or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma and FGFR alterations. In this study, the combination of erdafitinib and cetrelimab demonstrated clinically meaningful responses in cis-ineligible patients with first-line metastatic urothelial carcinoma and FGFR alterations. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.